Pfizer Inc. $PFE Shares Purchased by Penn Davis Mcfarland Inc.

Key Points

• Penn Davis Mcfarland Inc. increased its stake in Pfizer by 50.9% in Q4, adding 57,777 shares for a total of 171,332 shares valued at $4.266 million at quarter-end.
• Pfizer beat Q4 estimates with EPS of $0.66 (vs. $0.57 expected) and revenue of $17.56 billion (vs. $16.93 billion expected), and the stock is trading near its 12‑month high (open $28.56; 12‑month range $20.92–$28.64).
• Analysts have a consensus Hold rating with an average price target of $28.19, though some firms (HSBC, Morgan Stanley) are more positive, and institutional investors own about 68.36% of the stock.

Penn Davis Mcfarland Inc. grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 50.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 171,332 shares of the biopharmaceutical company's stock after acquiring an additional 57,777 shares during the quarter. Penn Davis Mcfarland Inc.'s holdings in Pfizer were worth $4,266,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Franklin Resources Inc. lifted its holdings in Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Neuberger Berman Group LLC grew its holdings in shares of Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock worth $229,346,000 after buying an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after buying an additional 5,978,927 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Pfizer by 120.9% in the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock valued at $230,986,000 after buying an additional 5,202,884 shares during the last quarter. Finally, Amundi lifted its stake in shares of Pfizer by 10.8% during the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock valued at $1,096,380,000 after buying an additional 4,043,413 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PFE shares. HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, March 17th. TD Cowen reissued a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 24th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the stock a "positive" rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $28.19.

Pfizer Stock Performance

Pfizer stock opened at $28.56 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.64. The company has a market capitalization of $162.41 billion, a price-to-earnings ratio of 21.00 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm's fifty day moving average price is $26.99 and its 200 day moving average price is $25.77.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company's revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court ordered Poland and Romania to accept €1.9B (~$2.2B) of Pfizer COVID-19 vaccines, effectively locking in substantial near-term revenue and reducing delivery/collection uncertainty. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Analyst/market write-ups highlight PFE’s recent outperformance and upward technical momentum (trading above its 50- and 200-day SMAs, and positive earnings beats), which supports demand for the stock. Why Pfizer (PFE) Outpaced the Stock Market Today
• Positive Sentiment: Fresh real‑world data from a Swedish study on Ibrance (palbociclib) offers an incremental clinical signal for Pfizer’s oncology franchise, supporting pipeline upside expectations. Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors
• Neutral Sentiment: Pfizer finalized reshaping of ViiV Healthcare ownership (GSK/Shionogi deal) as it exits the joint HIV venture — a strategic reallocation that may free capital but reduces direct exposure to that HIV business. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Background and business-model pieces continue to circulate (how Pfizer makes money, sector commentary), useful for context but not immediate catalysts. How Pfizer Makes Money
• Negative Sentiment: Pfizer and BioNTech paused U.S. recruitment for a large updated COVID vaccine trial (adults 50–64) due to low enrollment — a setback for collecting pivotal U.S. data and could delay future vaccine updates or label expansion. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Critical pieces argue Pfizer’s large dividend may mask underlying growth challenges, keeping longer-term valuation concerns on investors’ radar. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem
• Negative Sentiment: Reports that Pfizer will close its South San Francisco research site may signal internal cost-cutting or pipeline reprioritization; this can be seen as short-term disruption to R&D capacity. Pfizer is said to close South San Francisco research site

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.